Ming Yin

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

Ludwig Kappos, David Li, Peter A. Calabresi et al. · The Lancet · 2011 · 730 citations

Relapsing-remitting Multiple Sclerosis, Immunology, Clinical Trials +8

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

Anthony R. Mato, Nirav N. Shah, Wojciech Jurczak et al. · The Lancet · 2021 · 432 citations · Full text

Phase 1/2, Lymphoid Neoplasia, Medicine +6

Resveratrol alleviates MPTP‐induced motor impairments and pathological changes by autophagic degradation of α‐synuclein via SIRT1‐deacetylated LC3

Yanjie Guo, Su‐Yan Dong, Xin‐Xin Cui et al. · Molecular Nutrition & Food Research · 2016 · 189 citations

Rituximab Pharmacokinetics in Patients With Rheumatoid Arthritis: B‐Cell Levels Do Not Correlate With Clinical Response

Ferdinand C. Breedveld, Sunil Agarwal, Ming Yin et al. · The Journal of Clinical Pharmacology · 2007 · 144 citations

Immunology, Pharmacotherapy, Immunotherapy +21

Neuroprotective effects of arachidonic acid against oxidative stress on rat hippocampal slices

Zejian Wang, Cui-Ling Liang, Guang-Mei Li et al. · Chemico-Biological Interactions · 2006 · 125 citations

Medicine, Arachidonic Acid, Lipid Peroxidation +8